Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 2 3 4 5 … 47 Next »

Phase 2 study of PN-235 in psoriasis starts early 2022

Threaded Mode
Phase 2 study of PN-235 in psoriasis starts early 2022
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 54,272
Threads: 3,449
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 2
PQOLS: 2
Treatment: Ilumetri / Coconut Oil
#1
News  Fri-03-12-2021, 13:44 PM
Protagonist therapeutics announces the selection of oral peptide PN-235 into phase 2 clinical development program for multiple indications including psoriasis.

Quote:
Protagonist Therapeutics today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen). In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases (IBD) are expected to commence in late 2022. Further development of PN-232 (JNJ-7510586) will be discontinued in favor of PN-235 based on its superior potency, and overall pharmacokinetic and pharmacodynamic profile.

"We are delighted to see PN-235 emerge as the clear focal point going forward, after over four-plus years of a highly productive and ongoing collaboration with Janssen," said Dinesh V. Patel, PhD, President and CEO of Protagonist. "We look forward to exploring the full potential of a highly differentiated, oral targeted therapy like PN-235, thereby potentially addressing persistent unmet needs of patients with immune-mediated diseases like psoriasis and IBD."

Protagonist will earn a $25 million milestone in connection with the initiation of the first Phase 2 study of PN-235 in psoriasis in early 2022. Protagonist is also eligible for a $10 million milestone in connection with the start of the second indication-based Phase 2 study. Protagonist is eligible for up to approximately $900 million in development-related milestone payments, in addition to the $87.5M in milestones already earned. Under the terms of the collaboration, Janssen will conduct all future clinical studies, including these anticipated Phase 2 studies, and will be solely financially responsible for any such studies.

Source: protagonist-inc.com
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News IMG-004 starts phase I clinical trial Fred 2 90 Yesterday, 06:48 AM
Last Post: Caroline
News Bimzelx psoriatic arthritis phase 3 results Fred 4 810 Sat-22-01-2022, 10:05 AM
Last Post: Caroline
News Sleep disturbance in psoriasis [Study] Fred 5 977 Mon-17-01-2022, 21:05 PM
Last Post: jiml
News Piclidenoson for psoriasis report before phase 3 data release Fred 0 426 Fri-14-01-2022, 15:24 PM
Last Post: Fred
News Otezla phase 3 study in moderate to severe genital psoriasis Fred 3 725 Wed-08-12-2021, 02:26 AM
Last Post: KatT



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2022 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB
Linear Mode
Threaded Mode